Verona Pharma (VRNA) Stock Statistics & Valuation Metrics

Verona Pharma has a market cap or net worth of $5.97B. The enterprise value is ―.

Verona Pharma has 85,132,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Verona Pharma’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -37.99%.

The current PE Ratio of Verona Pharma is -21.84. Verona Pharma’s PEG ratio is -5.05.

In the last 12 months, Verona Pharma had revenue of 42.28M and earned -173.42M in profits. Earnings per share was -2.16.

In the last 12 months, operating cash flow was -119.80M and capital expenditures -519.01K, giving a free cash flow of -120.37M billion.

Verona Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Verona Pharma upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Verona Pharma as a current ratio of 10.63, with Debt / Equity ratio of 0.94%

In the past 12 months, Verona Pharma has paid 10.29M in taxes.

Verona Pharma EV to EBITDA ratio is -211.10, with an EV/FCF ratio of -244.47.

Verona Pharma has $401.42M in cash and marketable securities with $2.13M in debt, giving a net cash position of -$399.28M billion.

Gross margin is 94.72%, with operating margin of -365.73%, and net profit margin of -410.18%.

The average price target for Verona Pharma is $90.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy